Why is Glenmark Pharma falling/rising?

As of 18-Aug, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at Rs 1,974.40, which reflects a decrease of Rs 64.55 or 3.17%. The stock has underperformed its sector today by 3.4%, reaching an intraday low of Rs 1,949, which is a drop of 4.41%. Over the past week, the stock has decreased by 3.52%, and in the last month, it has fallen by 11.19%. Despite these short-term declines, the stock has shown strong performance over the longer term, with a year-to-date increase of 22.72% and a remarkable 394.09% rise over the past three years. The company maintains a low Debt to EBITDA ratio of 1.00 times, indicating a strong ability to service its debt, and has high institutional holdings at 38.3%, which suggests confidence from more knowledgeable investors.
In the broader market context, the stock's recent performance contrasts with the Sensex, which has gained 0.83% over the past week and is down only 0.59% in the last month. This indicates that while Glenmark Pharmaceuticals is facing challenges, the overall market is relatively stable. The stock's liquidity remains adequate, with a delivery volume increase of 227.62% on August 14, suggesting rising investor participation. However, the stock's movement below its 5-day and 20-day moving averages may indicate short-term bearish sentiment among investors, contributing to its current price decline.